ArticleJournal of clinical medicine2020
B-Type Natriuretic Peptide as Biomarker of COVID-19 Disease Severity-A Meta-Analysis.
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Meta-analysis of cardiac markers for predictive factors on severity and mortality of COVID-19.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- Association of Abnormal Cardiac Biomarkers and Cardiovascular Complications, with Mortality in Patients with SARS-CoV-2 Infection in Latin America.Journal of cardiovascular development and disease · 2024Article
- Association between echocardiographic features, troponin levels, and survival time in hospitalized COVID-19 patients with cardiovascular events.Journal of anesthesia and translational medicine · 2024Article
- NT-proBNP ratio is a potential predictor for COVID-19 outcomes in adult Chinese patients: a retrospective study.Scientific reports · 2024Observational
- Evaluation of various blood biomarkers associated with the outcomes of patients with COVID‑19 treated in intensive care units.Experimental and therapeutic medicine · 2024Article
- Baseline NT-proBNP levels as a predictor of short-and long-term prognosis in COVID-19 patients: a prospective observational study.BMC infectious diseases · 2024Observational
- Natural Course of COVID-19 and Independent Predictors of Mortality.Biomedicines · 2023Article
- Rapid Assessment of COVID-19 Mortality Risk with GASS Classifiers.Biomedicines · 2023Article
- Natriuretic Peptides as Biomarkers: Narrative Review and Considerations in Cardiovascular and Respiratory Dysfunctions.The Yale journal of biology and medicine · 2023Review
- Pathophysiological effects of SARS-CoV-2 infection on the cardiovascular system and its clinical manifestations-a mini review.Frontiers in cardiovascular medicine · 2023Review
- Cardiovascular markers and COVID-19.Materials today. Proceedings · 2023Article
- Deep Survival Analysis With Clinical Variables for COVID-19.IEEE journal of translational engineering in health and medicine · 2023Article
- Utility of cardiac bioenzymes in predicting cardiovascular outcomes in SARS-CoV-2.World journal of virology · 2022Article
- The use of cardiac troponins and B-type natriuretic peptide in COVID-19.Acta cardiologica · 2022Review
- A Real Pandora's Box in Pandemic Times: A Narrative Review on the Acute Cardiac Injury Due to COVID-19.Life (Basel, Switzerland) · 2022Review
- Review
- Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19.Frontiers in immunology · 2022Review
- Vasoactive Peptides: Role in COVID-19 Pathogenesis and Potential Use as Biomarkers and Therapeutic Targets.Archives of medical research · 2021Review
- Admission NT-proBNP and outcomes in patients without history of heart failure hospitalized with COVID-19.ESC heart failure · 2021Article
- Characterization of NT-proBNP in a large cohort of COVID-19 patients.European journal of heart failure · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Up to 15% of coronavirus disease 2019 (COVID-19) patients experience severe clinical presentation, resulting in acute respiratory distress (ARDS) and finally death. N-terminal natriuretic peptide (NT-proBNP) is associated with a worse prognosis in patients with ARDS. However, whether or not this peptide can help discriminate high-risk COVID-19 patients remains unclear. Therefore, in this meta-analysis, we summarized the available evidence on NT-proBNP in patients admitted for COVID-19. Pooled mean, mean differences (MD) and standardized mean difference (SMD) were the summary metrics. Thirteen studies were finally selected for this analysis with a total of 2248 patients, of which 507 had a severe condition (n = 240) or died (n = 267). Pooled mean NT-proBNP levels on admission were 790.57 pg/mL (95% confidence intervals (CIs): 532.50 to 1048.64) in patients that experienced a severe clinical condition or died, and 160.56 pg/mL (95% CI: 118.15 to 202.96) in non-severe patients (SMD: 1.05; 95% (CI): 0.83 to 1.28;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.